Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06636526 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

The i4i PRODICT® Study: Evaluation of the i4i PRODICT® Test in Different Ethnic Groups (The i4i PRODICT® Study).

StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary endpoint revisedv3 Show 5 more changesShow less
    • Interventions: MRI Scan (Procedure), Prostate Biopsy (Procedure), Prostate cancer screening (Other), The i4i PRODICT™ test. (Genetic) to MRI Scan (Procedure), Prostate Biopsy (Procedure), Prostate cancer screening (Other), The i4i PRODICT® test. (Genetic)
    • Study description expanded, about 132 words
    • Site details revised at 1 of 3 sites
    • Study title revised
    • Eligibility criteria shortened, about 3 words
  2. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Jan 6, 2025 to Jun 2, 2025
    • Study sites: 1 to 3
    v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The i4i PRODICT® study has been developed to investigate the uptake and acceptability of the i4i PRODICT® test which combines both common and rare genetic changes (genetic variants) into one saliva-based DNA test to estimate a person's future risk of prostate cancer (PrCa) in people of varying ethnicities.
Trial Details
NCT Number NCT06636526
Lead Sponsor Institute of Cancer Research, United Kingdom
Collaborators: Royal Marsden NHS Foundation Trust, Imperial College London
Conditions
(from sponsor)		 Prostate Cancer
Related terms Genetic Predisposition to Disease, Genetic Risk Score, Prostatic Neoplasms
Enrollment 1,000 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov